As expected in this model, anti-PD-L1 ICB exerted no therapeutic benefit, whereas both nAlb-diABZI and AP-diABZI suppressed tumor growth and elongated median survival, with AP-diABZI conferring the most survival benefit, consistent with findings in the EMT6 model (Fig. 7a–d). This evidence concerns the gene CD274 and neoplasm.